ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading
Two former political rivals in the UK have joined forces to write a strategy to keep the country at the forefront of the biotech and artificial intelligence sectors – and
Momentum seems to be building behind biotech financings as the first month of 2023 draws to a close, with a respectable raise for cancer start-up Synnovation Therapeutics
2023 was a tough year for biotechs with declines in private fundraising and public listings, but the UK industry stood up well under the pressure, according to new figures